Elysium Therapeutics Funding Round

1/28/2026

Venture Equity

$7,500,000

Undisclosed

The company intends to accelerate development of its SOOPR (Synthetic Opioid Overdose Protection and Reversal) technology designed specifically as a rescue treatment for overdoses brought on by synthetic opioids, including fentanyl and the emerging threat of more potent nitazenes.

Private & Independent

Biopharmaceutical

57 Ogallala Rd
Lyons, CO 80540
US

Elysium's mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that address the key limitations and dangers associated with opioids used today. Our pipeline consists of 3 diverse platforms with broad applicability across several areas of significant unmet need: Technologies 1. O2P� (Oral Overdose Protection) -- Lead platform Traditional opioids are easy to abuse, with euphoria and risk of respiratory depression increasing with every pill consumed. O2P provides self-limiting exposure to active opioid and prevents overdose. 2. XpiRx� (Forced Expiration) 70-year half-life of traditional opioids creates a surplus supply of readily available pills that can end up on the streets. XpiRx opioids, whose potency expires after the prescribed-use period, reduce abuse and prevent fatal overdoses. 3. SOOPR� (Synthetic Opioid Overdose Prevention and Rescue) Existing rescue agents are